The 23rd Congress of the European Hematology Association (EHA) took place June 14-17, 2018, in Stockholm, Sweden.

Drug proves active in resistant MM

Print Friendly, PDF & Email


Poster session at the 23rd
Congress of the European
Hematology Association (EHA)
Photo from EHA
The alkylating peptide melflufen has demonstrated activity in patients with treatment-resistant multiple myeloma (MM). In a phase 2 trial, melflufen plus dexamethasone produced an overall response rate (ORR) of 32.1% in MM patients who were refractory to pomalidomide and/or... [Read Article]
Print Friendly, PDF & Email

‘Very encouraging’ results in BPDCN

Print Friendly, PDF & Email


The 23rd Congress of the
European Hematology Association (EHA)
Photo from EHA
Tagraxofusp (SL-401) has produced “very encouraging” results in a phase 2 trial of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to an investigator. Tagraxofusp, a targeted therapy directed to CD123, produced an overall response rate (ORR) of 83% and a... [Read Article]
Print Friendly, PDF & Email

Doc reports favorable results from trial on hold

Print Friendly, PDF & Email


Session at the 23rd
Congress of the European
Hematology Association (EHA)
Photo from EHA
Interim trial results suggest the EZH2 inhibitor tazemetostat can produce durable responses in patients with relapsed or refractory follicular lymphoma (FL). In patients with EZH2 mutations, the overall response rate (ORR) was 71%, and the median duration of response (DOR) was... [Read Article]
Print Friendly, PDF & Email

Ropeg outperforms HU in PV patients of all ages

Print Friendly, PDF & Email


The 23rd Congress of the
European Hematology Association
Follow-up data suggest that ropeginterferon alfa-2b (ropeg) provides an advantage over hydroxyurea (HU) for patients with polycythemia vera (PV), regardless of their age. Two-year results from an extension study have shown that, compared to HU, ropeg produces higher rates of complete hematologic response (CHR) and molecular response... [Read Article]
Print Friendly, PDF & Email

A ‘highly effective’ strategy for haplo-HSCT

Print Friendly, PDF & Email


Daria Pagliara, MD, PhD
Researchers have identified a “highly effective” transplant strategy for pediatric patients with primary immunodeficiencies who lack a suitable HLA-compatible donor, according to a speaker at the 23rd Congress of the European Hematology Association (EHA). The strategy involves α/β T-cell- and B-cell-depleted haploidentical hematopoietic stem cell transplant (haplo-HSCT) followed by infusion of... [Read Article]
Print Friendly, PDF & Email

Voxelotor benefits adolescents with SCD

Print Friendly, PDF & Email


Attendees at the 23rd
Congress of the European
Hematology Association (EHA)
Photo from EHA
An ongoing phase 2 study suggests voxelotor (GBT440) can benefit adolescents with sickle cell disease (SCD). In the HOPE-KIDS 1 study, voxelotor produced sustained improvements in hemoglobin levels and a reduction in clinical measures of hemolysis in a cohort of adolescents... [Read Article]
Print Friendly, PDF & Email

Survey reveals patient perceptions of ITP

Print Friendly, PDF & Email


Poster session at the 23rd
Congress of the European
Hematology Association (EHA)
Photo from EHA
A new survey has revealed patients’ perceptions of immune thrombocytopenia (ITP) and how the condition impacts their quality of life (QOL). Patients reported delays in diagnosis, lack of support, severe fatigue, and impacts on both emotional well-being and their ability... [Read Article]
Print Friendly, PDF & Email

Drug is convenient alternative for PNH, doc says

Print Friendly, PDF & Email


Session at the 23rd
Congress of the European
Hematology Association (EHA)
Photo from EHA
Results of a phase 3 study suggest the long-acting C5 complement inhibitor ravulizumab produces similar results as eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH). Treatment with ravulizumab every 8 weeks proved noninferior to treatment with eculizumab every 2 weeks... [Read Article]
Print Friendly, PDF & Email

Inhibitor elicits responses in cGVHD

Print Friendly, PDF & Email


Amandeep Salhotra, MD
The ROCK2 inhibitor KD025 produced responses in about two-thirds of patients with steroid-dependent or refractory chronic graft-versus-host disease (cGVHD) in a phase 2 trial. KD025 elicited improvements in Lee Symptom Scale score, and patients were able to reduce doses of corticosteroids and other immunosuppressants. There were no serious adverse events (AEs)... [Read Article]
Print Friendly, PDF & Email

MAb doubles ORR, PFS in rel/ref MM

Print Friendly, PDF & Email


Elotuzumab
Photo courtesy of
Bristol-Myers Squibb
Adding elotuzumab (E) to treatment with pomalidomide (P) and low-dose dexamethasone (d) can produce “clinically meaningful” results in patients with relapsed/refractory multiple myeloma (MM), according to an investigator for the ELOQUENT-3 trial. In this phase 2 trial, patients who received EPd had double the overall response rate (ORR)... [Read Article]
Print Friendly, PDF & Email

Inhibitor exhibits activity in B- and T-cell NHLs

Print Friendly, PDF & Email


Poster session at the 23rd
Congress of the European
Hematology Association
The dual SYK/JAK inhibitor cerdulatinib has demonstrated efficacy in a phase 2 trial of patients with heavily pretreated B- and T-cell non-Hodgkin lymphomas (NHLs). There were a few deaths due to sepsis or septic shock that were considered related to cerdulatinib, but investigators... [Read Article]
Print Friendly, PDF & Email

Combo proves ‘beneficial’ for ‘unfit’ CLL patients

Print Friendly, PDF & Email


Valentin Goede, MD
Obinutuzumab plus chlorambucil (G-Clb) is a “valid and beneficial” frontline treatment option for “unfit” patients with chronic lymphocytic leukemia (CLL), according to a speaker at the 23rd Congress of the European Hematology Association (EHA). Final results from the CLL11 study have revealed additional benefits of G-Clb over rituximab plus chlorambucil (R-Clb) in... [Read Article]
Print Friendly, PDF & Email

Umbralisib can revitalize ruxolitinib in MF

Print Friendly, PDF & Email


Poster session at the 23rd Congress of the European Hematology Association
The PI3K delta inhibitor umbralisib can “augment or resurrect” responses to ruxolitinib in patients with myelofibrosis (MF), according to a speaker at the 23rd Congress of the European Hematology Association (EHA). Results of a phase 1 study showed that adding umbralisib to treatment with... [Read Article]
Print Friendly, PDF & Email

Quizartinib can prolong OS in rel/ref, FLT3-ITD AML

Print Friendly, PDF & Email


The 23rd Congress of the European Hematology Association
Phase 3 results suggest the FLT3 inhibitor quizartinib can prolong overall survival (OS) in patients with relapsed/refractory, FLT3-ITD acute myeloid leukemia (AML). In the QuANTUM-R study, patients who received single-agent quizartinib had a significantly longer median OS than patients who received salvage chemotherapy. There was a... [Read Article]
Print Friendly, PDF & Email